BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38173340)

  • 1. Healthcare center-based cell therapy laboratories supporting off-site manufactured cell therapies: The experiences of a single academic cell therapy laboratory.
    Dinh A; Stroncek DF
    Transfusion; 2024 Feb; 64(2):357-366. PubMed ID: 38173340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The need for uniform and coordinated practices involving centrally manufactured cell therapies.
    Stroncek D; Dinh A; Rai H; Zhang N; Somerville R; Panch S
    J Transl Med; 2022 Apr; 20(1):184. PubMed ID: 35468789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Processing laboratory considerations for multi-center cellular therapy clinical trials: a report from the Consortium for Pediatric Cellular Immunotherapy.
    Lindgren C; Leinbach A; Annis J; Tanna J; Zhang N; Esensten JH; Hanley PJ
    Cytotherapy; 2021 Feb; 23(2):157-164. PubMed ID: 33189573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accommodating clinical trials and other externally manufactured cellular therapy products: challenges, lessons learned and creative solutions.
    Jackson MR
    Cytotherapy; 2022 Jan; 24(1):37-44. PubMed ID: 34305008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expanding the reach of commercial cell therapies requires changes at medical centers.
    Stroncek DF; Zhang N; Ren J; Somerville R; Dinh A
    J Transl Med; 2024 Feb; 22(1):181. PubMed ID: 38374090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variations in novel cellular therapy products manufacturing.
    Fontaine MJ; Selogie E; Stroncek D; McKenna D; Szczepiorkowski ZM; Takanashi M; Garritsen H; Girdlestone J; Reems JA;
    Cytotherapy; 2020 Jun; 22(6):337-342. PubMed ID: 32223996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of contracted manufacturing organization protocols on operations in an aca demically based Current Good Manufacturing Practice facility.
    Sutherland V; Buffo MJ; Whiteside TL
    Cytotherapy; 2022 Jan; 24(1):32-36. PubMed ID: 33610480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paving the Road for Chimeric Antigen Receptor T Cells: American Society for Transplantation and Cellular Therapy 80/20 Task Force Consensus on Challenges and Solutions to Improving Efficiency of Clinical Center Certification and Maintenance of Operations for Commercially Approved Immune Effector Cell Therapies.
    Nikiforow S; Frigault MJ; Frey NV; Gardner RA; Komanduri KV; Perales MA; Kebriaei P; Warkentin PI; Pasquini M; Aho JL; Levine BL; Heslop HE; Hlucky TL; Habucky K; Gharibo M; Jagasia M; Locke FL
    Transplant Cell Ther; 2023 Apr; 29(4):228-239. PubMed ID: 36709800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How do I structure logistic processes in preparation for outsourcing of cellular therapy manufacturing?
    Chen LN; Collins-Johnson N; Sapp N; Pickett A; West K; Stroncek DF; Panch SR
    Transfusion; 2019 Aug; 59(8):2506-2518. PubMed ID: 31135995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Technological progress and challenges towards cGMP manufacturing of human pluripotent stem cells based therapeutic products for allogeneic and autologous cell therapies.
    Abbasalizadeh S; Baharvand H
    Biotechnol Adv; 2013 Dec; 31(8):1600-23. PubMed ID: 23962714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Establishment of a cell processing laboratory to support hematopoietic stem cell transplantation and chimeric antigen receptor (CAR)-T cell therapy.
    Mukherjee S; Reddy O; Panch S; Stroncek D
    Transfus Apher Sci; 2021 Feb; 60(1):103066. PubMed ID: 33472742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon.
    Drugs R D; 2006; 7(3):197-201. PubMed ID: 16752945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Automation of cellular therapy product manufacturing: results of a split validation comparing CD34 selection of peripheral blood stem cell apheresis product with a semi-manual vs. an automatic procedure.
    Hümmer C; Poppe C; Bunos M; Stock B; Wingenfeld E; Huppert V; Stuth J; Reck K; Essl M; Seifried E; Bonig H
    J Transl Med; 2016 Mar; 14():76. PubMed ID: 26983643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Off the shelf cellular therapeutics: Factors to consider during cryopreservation and storage of human cells for clinical use.
    Woods EJ; Thirumala S; Badhe-Buchanan SS; Clarke D; Mathew AJ
    Cytotherapy; 2016 Jun; 18(6):697-711. PubMed ID: 27173747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Point-of-care cell therapy manufacturing; it's not for everyone.
    Stroncek DF; Somerville RPT; Highfill SL
    J Transl Med; 2022 Jan; 20(1):34. PubMed ID: 35033098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GMP-conformant on-site manufacturing of a CD133
    Skorska A; Müller P; Gaebel R; Große J; Lemcke H; Lux CA; Bastian M; Hausburg F; Zarniko N; Bubritzki S; Ruch U; Tiedemann G; David R; Steinhoff G
    Stem Cell Res Ther; 2017 Feb; 8(1):33. PubMed ID: 28187777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endogenous microbial contamination of cultured autologous preparations in trials of cancer immunotherapy.
    Padley DJ; Greiner CW; Heddlesten TL; Hopkins MK; Maas ML; Gastineau DA
    Cytotherapy; 2003; 5(2):147-52. PubMed ID: 12769074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [CAR T cells as drugs for novel therapies (advanced therapy medicinal products)].
    Köhl U; Abken H
    Internist (Berl); 2021 Apr; 62(4):449-457. PubMed ID: 33590292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of routine evaluation of sterility of cellular therapy products with or without extensive manipulation: Best practices and clinical significance.
    Golay J; Pedrini O; Capelli C; Gotti E; Borleri G; Magri M; Vailati F; Passera M; Farina C; Rambaldi A; Introna M
    Cytotherapy; 2018 Feb; 20(2):262-270. PubMed ID: 29246649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What does cell therapy manufacturing cost? A framework and methodology to facilitate academic and other small-scale cell therapy manufacturing costings.
    Ten Ham RMT; Hövels AM; Hoekman J; Frederix GWJ; Leufkens HGM; Klungel OH; Jedema I; Veld SAJ; Nikolic T; Van Pel M; Zwaginga JJ; Lin F; de Goede AL; Schreibelt G; Budde S; de Vries IJM; Wilkie GM; Dolstra H; Ovelgönne H; Meij P; Mountford JC; Turner ML; Hoefnagel MHN
    Cytotherapy; 2020 Jul; 22(7):388-397. PubMed ID: 32414635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.